Rostock International Parkinson's Disease Study - An international, multicentre, epidemiological observational study (ROPAD)

Date Added
February 11th, 2020
PRO Number
Pro00095796
Researcher
Vanessa Hinson

List of Studies

Keywords
Parkinsons
Summary

This study is collecting information to determine if there is a genetic factor contributing to the development of Parkinson's disease. Adults with Parkinson's disease or individuals that have family members with Parkinson's disease may qualify to participate in this study. All participants that qualify to enroll will have their medical history recorded, a brief neurological examination will be performed and blood will be drawn for genetic analysis. All information collected will be coded to protect participants privacy. No other procedures are involved in this study because it is not a treatment study.

Institution
MUSC
Recruitment Contact
Sandra Wilson
843-792-4616
wilsosan@musc.edu

A RANDOMIZED CONTROLLED STUDY TO COMPARE THE SAFETY AND EFFICACY OF IPX203 WITH IMMEDIATE-RELEASE CARBIDOPA-LEVODOPA IN PARKINSON'S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS

Date Added
July 28th, 2019
PRO Number
Pro00088773
Researcher
Vanessa Hinson

List of Studies

Keywords
Drug Studies, Parkinsons, Stage III
Summary

IPX203 is an investigational extended-release (i.e. releases drug more slowly) capsule formulation of carbidopa-levodopa (CD-LD) administered orally (by mouth). "Investigational" means that IPX203 is being tested and has not been approved for marketing.

IPX203 is being investigated to determine whether the drug is safe and potentially has a better effect than currently approved IR CD-LD. If successful, the drug could possibly improve the daily control of motor symptoms in people with Parkinson's disease.

IPX203 is provided as a capsule containing 140 mg LD and 35 mg CD. The study doctor may adjust the IPX203 dosing regimen based on your response to the study drug during the 4 week dose conversion period. Your study doctor will instruct you on the dose of IPX203 or IPX203 placebo that you will receive during the 13-week portion of the study.

Your total participation time in the study will be approximately 24 weeks (6 months), which includes 4 weeks for your initial assessment (screening) period to determine if the trial is suitable for you.

Institution
MUSC
Recruitment Contact
Lisa Heidelberg
843-792-9115
heidelbe@musc.edu

Transcutaneous auricular Vagal Nerve Stimulation (taVNS) in mild to moderate Parkinson's Disease

Date Added
March 20th, 2018
PRO Number
Pro00073767
Researcher
Vanessa Hinson

List of Studies

Keywords
Parkinsons
Summary

An investigator initiated pilot study of transcutaneous auricular vagal nerve stimulation (taVNS) in mild to moderate Parkinson's disease (PD).

We will assess whether nerve stimulation done on the surface of the skin, (called transcutaneous vagus nerve stimulation (taVNS)) is safe and effective in people with Parkinson's Disease (PD). A small electrical stimulator will be used to deliver electric pulses to a small portion of the left ear of the study participants. Participants will be assigned by chance to either 2 weeks of treatment with real taVNS, or a sham stimulation. The investigator will rate PD motor and cognitive symptoms before, during, and after the 2-week cycle. The investigators will also perform a number of blood and eye movement tests to check for the effectiveness of the stimulation, and perform regular safety checks.

Institution
MUSC
Recruitment Contact
Lisa Heidelberg
843-792-9115
heidelbe@musc.edu



-- OR --